Pooled TETON‑1/2 trials met the primary endpoint, demonstrating significantly less 52‑week FVC loss with inhaled treprostinil than placebo. Efficacy signals extended to secondary outcomes, reducing ...
Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF). How does the rate of ...
The quality control of variants from whole-genome sequencing data is vital in clinical diagnosis and human genetics research. However, current filtering methods (Frequency, Hard-Filter, VQSR, GARFIELD ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral nerandomilast doses of 9 mg and 18 mg were ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Two differing doses of deupirfenidone were assessed ...
SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results